Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling

Published on Dec 1, 2015in Molecular Medicine Reports1.851
· DOI :10.3892/mmr.2015.4422
Jong Bin Kim11
Estimated H-index: 11
(SNU: Seoul National University),
Minjong Lee18
Estimated H-index: 18
(SNU: Seoul National University)
+ 5 AuthorsYoon Jun Kim39
Estimated H-index: 39
(SNU: Seoul National University)
Abstract Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). The aim of the present study was to evaluate the anticancer effect of sorafenib in cancer stem cell‑like cells, such as side population (SP) cells, in HCC and to analyze the signaling pathway for drug‑resistance. To evaluate the anticancer effects of sorafenib, Huh7 and Huh‑BAT cells were treated with sorafenib, fluorouracil (5‑FU), and sorafenib plus 5‑FU. These cells were examined for growth rates, the SP fraction, sphere‑forming efficacy and expression of c‑Jun N‑terminal kinase (JNK) signaling molecules. Sorafenib and 5‑FU treatment decreased growth rates in Huh7 and Huh‑BAT cells; however, the treatments exerted different effects in SP cells and on the expression levels of JNK signaling molecules. Treatment with 5‑FU increased the SP cell number and upregulated the expression of JNK signaling molecules. By contrast, sorafenib decreased the SP cell number and downregulated the expression of JNK signaling molecules. No significant differences in sphere‑forming efficacy were observed subsequent to 5‑FU and sorafenib treatment in Huh7 and Huh‑BAT cells. These results indicate that sorafenib exerted anticancer effects in HCC and SP cells by targeting JNK signaling.
  • References (23)
  • Citations (0)
#1Mario Scartozzi (Marche Polytechnic University)H-Index: 33
#2Luca Faloppi (Marche Polytechnic University)H-Index: 20
Last. Stefano Cascinu (Marche Polytechnic University)H-Index: 53
view all 25 authors...
Although new treatment modalities changed the global approach to hepatocellular carcinoma (HCC), this disease still represents a medical challenge. Currently, the therapeutic stronghold is sorafenib, a tyrosine kinase inhibitor (TKI) directed against the vascular endothelial growth factor (VEGF) family. Previous observations suggested that polymorphisms of VEGF and its receptor (VEGFR) genes may regulate angiogenesis and lymphangiogenesis and thus tumour growth control. The aim of our study was ...
59 CitationsSource
#1Ágnes Telbisz (MTA: Hungarian Academy of Sciences)H-Index: 9
#2Csilla Hegedüs (MTA: Hungarian Academy of Sciences)H-Index: 11
Last. Csilla Özvegy-LaczkaH-Index: 22
view all 5 authors...
ABCG2 (ATP-binding cassette, subfamily G, member 2) is a plasma membrane glycoprotein that actively extrudes xenobiotics and endobiotics from the cells and causes multidrug resistance in cancer. In the liver, ABCG2 is expressed in the canalicular membrane of hepatocytes and excretes its substrates into the bile. ABCG2 is known to require high membrane cholesterol content for maximal activity, and by examining purified ABCG2 reconstituted in proteoliposomes we have recently shown that cholesterol...
20 CitationsSource
#1Qian Jia (CQMU: Chongqing Medical University)H-Index: 2
#2Xiao-Li Zhang (CQMU: Chongqing Medical University)H-Index: 2
Last. Jian Gao (CQMU: Chongqing Medical University)H-Index: 1
view all 4 authors...
Abstract Liver cancer is one of the most common tumors worldwide and drug resistance is a major obstacle to successful therapy. The growing data show that cancer stem cells (CSCs), a rare subpopulation of cancer cells, might be an important mechanism of drug resistance. To explore the self-renewal ability and chemotherapy resistance in liver CSCs, we enriched CD90+CD133+ hepatocellular carcinoma (HCC) CSCs using sphere formation, which was accomplished by cultivating HCC CSCs from established HC...
30 CitationsSource
#1C. Xue (SYSU: Sun Yat-sen University)H-Index: 1
#2Yan Huang (SYSU: Sun Yat-sen University)H-Index: 28
Last. Li ZhangH-Index: 1
view all 20 authors...
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma† C. Xue1,2,, Y. Huang1,2,, P. Y. Huang1,3,, Q. T. Yu5, J. J. Pan6, L. Z. Liu1,4, X. Q. Song5, S. J. Lin6, J. X. Wu1,2,, J. W. Zhang1,2, H. Y. Zhao1,2, F. Xu1,2, J. L. Liu1,2, Z. H. Hu1,2, L. P. Zhao1,2, Y. Y. Zhao1,2, X. Wu1,2, J. Zhang1,2, Y. X. Ma1,2 & L. Zhang1,2* State Key Laboratory of Oncology in South China; Departments of Medical Oncology; Nasopharyngeal ...
28 CitationsSource
#1Jae Ho LeeH-Index: 2
#2Jae Woong ShimH-Index: 6
Last. Kwangmo YangH-Index: 11
view all 5 authors...
The importance of anticancer stem cell research for breast cancer lies in the possibility of providing new approaches for an improved understanding of anticancer activity and cancer treatment. In this study, we demonstrated that the preclinical therapeutic efficacy of combining the multikinase inhibitor sorafenib with radiation was more effective in hypoxia-exposed breast cancer stem cells. We assessed cell viability and Annexin V to evaluate the combined effect of sorafenib and radiation follow...
12 CitationsSource
#1Elisa CarraH-Index: 8
#2Federica BarbieriH-Index: 33
Last. Antonio DagaH-Index: 30
view all 7 authors...
Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis. We investigated the effects of the multi-kinase inhibitor sorafenib on six cultures isolated from human glioblastomas and maintained in tumor initiating cells-enriching conditions. These cell subpopulations are thought to be responsible for tumor recurrence and radio- and chemo-resistance, representing the perfect target for glioblastoma therapy. Sorafenib reduces prol...
47 CitationsSource
#1Stephanie Ma (HKU: University of Hong Kong)H-Index: 31
Abstract Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, accounting for 80%–90% of all liver cancers. The disease ranks as the fifth most common cancer worldwide and is the third leading cause of all cancer-associated deaths. Although advances in HCC detection and treatment have increased the likelihood of a cure at early stages of the disease, HCC remains largely incurable because of late presentation and tumor recurrence. Only 25% of HCC patients are dee...
52 CitationsSource
#1Caecilia H. C. Sukowati (AREA Science Park)H-Index: 7
#2Natalia Rosso (AREA Science Park)H-Index: 15
Last. Claudio Tiribelli (UniTS: University of Trieste)H-Index: 57
view all 8 authors...
Background The Breast Cancer Resistance Protein (BCRP/ABCG2) is one member of ABC transporters proteins super family responsible of drug resistance. Since data on ABCG2 expression in liver malignances are scanty, here we report the expression of ABCG2 in adult human hepatocellular carcinoma (HCC) in both in vivo and in vitro models with different degree of malignancy.
29 CitationsSource
#1Chang-Hwan Yoon (Hanyang University)H-Index: 33
#2Mae-Ja KimH-Index: 1
Last. Su Jae Lee (Hanyang University)H-Index: 32
view all 11 authors...
c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells
64 CitationsSource
#1Xiaofei Qiu (Tianjin Medical University)H-Index: 5
#2Zhengyan Wang (Tianjin Medical University)H-Index: 3
Last. Yajing Luan (Tianjin Medical University)H-Index: 5
view all 6 authors...
Abstract A relatively novel paradigm in tumor biology hypothesizes that cancer growth is driven by tumor cells with stem-like properties. However, direct proof of a population of stem cells in small cell lung cancer (SCLC) remains elusive. In this study, we enriched for stem-like cells from the SCLC cell line H446 by growing them as spheres in a defined serum-free medium. Sphere-derived cells have increased in vitro clonogenic and in vivo tumorigenic potentials as well as drug-resistant properti...
53 CitationsSource
Cited By0
#1Jose J.G. Marin (University of Salamanca)H-Index: 38
#2Rocio I.R. Macias (University of Salamanca)H-Index: 30
Last. Maria Reviejo (University of Salamanca)H-Index: 1
view all 12 authors...
The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the availa...